IFNB1 and myeloid sarcoma: Exacerbating IFN-β-treated MS, compared to HC and exacerbating therapy-naive patients, had higher levels of a limited number of chemokines and Th1 cytokines, as well as several elevated Th2/regulatory cytokines (Fig 11).